Polar Capital Holdings Plc Has $53.77 Million Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Polar Capital Holdings Plc increased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 267.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,389,668 shares of the company's stock after acquiring an additional 1,739,668 shares during the period. Polar Capital Holdings Plc owned about 4.89% of Enliven Therapeutics worth $53,768,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ELVN. Tower Research Capital LLC TRC grew its position in Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after acquiring an additional 1,114 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Enliven Therapeutics in the 4th quarter valued at approximately $97,000. BNP Paribas Financial Markets acquired a new position in shares of Enliven Therapeutics during the 4th quarter worth approximately $112,000. ExodusPoint Capital Management LP acquired a new position in Enliven Therapeutics in the 4th quarter valued at $200,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Enliven Therapeutics during the 4th quarter worth $228,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN traded up $0.21 during trading on Tuesday, reaching $17.06. The stock had a trading volume of 76,273 shares, compared to its average volume of 263,299. The business has a fifty day moving average price of $18.76 and a 200-day moving average price of $21.58. The stock has a market cap of $836.87 million, a PE ratio of -8.98 and a beta of 1.07. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

ELVN has been the topic of a number of recent analyst reports. HC Wainwright lifted their price objective on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Jones Trading cut their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $37.25.

Insider Activity

In other news, COO Anish Patel sold 6,667 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $21.44, for a total transaction of $142,940.48. Following the sale, the chief operating officer now directly owns 323,310 shares of the company's stock, valued at $6,931,766.40. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $20.83, for a total value of $260,375.00. Following the completion of the transaction, the chief executive officer now directly owns 990,392 shares in the company, valued at approximately $20,629,865.36. The trade was a 1.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 76,111 shares of company stock worth $1,493,145. 29.20% of the stock is currently owned by insiders.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.